Osteoporosis among patients with type 1 and type 2 diabetes

被引:146
作者
Raekel, A. [1 ,2 ]
Sheehy, O. [1 ]
Rahme, E. [2 ]
LeLorier, J. [1 ]
机构
[1] CHUM, Res Ctr, Res Grp Pharmacoepidemiol & Pharmacoecon, Hotel Dieu, Montreal, PQ H2W 1T7, Canada
[2] McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada
关键词
Diabetes mellitus type 1 and type 2; Osteoporosis Osteopenia; Fractures; Bone mineral density; Review;
D O I
10.1016/j.diabet.2007.10.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Both diabetes and fractures are prevalent in adults. The relationship between diabetes and osteoporosis is complex and, although it has been investigated extensively. the subject remains controversial. While low bone mineral density (BMD) is consistently observed in type 1 diabetes, the relationship is less clear in type 2 diabetes, with some Studies reporting modestly increased or unchanged BMD. Both type I and type 2 diabetes have been associated with a higher risk of fractures. Despite discrepancies between BMD and fracture rates, clinical trials uniformly support the fact that new bone formation and bone microarchitecture and. thus, bone quality, are altered in both types of diabetes. Although a Causal association between diabetes and osteoporosis cannot be established on the basis of existing data, it is possible to conclude front many studies and from a better understanding of the physiopathology of diabetes that it can increase the risk of fractures through skeletal (decreased BMD and bone quality) and extraskeletal (increased risk of falls) factors. Even though osteoporosis screening or prophylactic treatment in all patients with type I and type 2 diabetes is not being recommended at present, such patient populations should be given general guidelines regarding calcium and vitamin D intakes. exercise and the avoidance of potential risk factors for osteoporosis. The extent of diagnostic and therapeutic interventions should be based on the individual's risk profile for fractures. (C) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:193 / 205
页数:13
相关论文
共 124 条
[1]   Bone metabolism in male patients with type 2 diabetes [J].
Achemlal, L ;
Tellal, S ;
Rkiouak, F ;
Nouijai, A ;
Bezza, A ;
Derouiche, E ;
Ghafir, D ;
El Maghraoui, A .
CLINICAL RHEUMATOLOGY, 2005, 24 (05) :493-496
[2]   Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts [J].
Akune, T ;
Ogata, N ;
Hoshi, K ;
Kubota, N ;
Terauchi, Y ;
Tobe, K ;
Takagi, H ;
Azuma, Y ;
Kadowaki, T ;
Nakamura, K ;
Kawaguchi, H .
JOURNAL OF CELL BIOLOGY, 2002, 159 (01) :147-156
[3]   PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors [J].
Akune, T ;
Ohba, S ;
Kamekura, S ;
Yamaguchi, M ;
Chung, UI ;
Kubota, N ;
Terauchi, Y ;
Harada, Y ;
Azuma, Y ;
Nakamura, K ;
Kadowaki, T ;
Kawaguchi, H .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (06) :846-855
[4]  
Al-Maatouq MA, 2004, SAUDI MED J, V25, P1423
[5]  
Albright F, 1948, AM J MED SCI, V174, P313
[6]   Bone density and markers of bone remodeling in type 1 male diabetic patients [J].
Alexopoulou, O. ;
Jamart, J. ;
Devogelaer, J. P. ;
Brichard, S. ;
de Nayer, P. ;
Buysschaert, M. .
DIABETES & METABOLISM, 2006, 32 (05) :453-458
[7]   Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation [J].
Ali, AA ;
Weinstein, RS ;
Stewart, SA ;
Parfitt, AM ;
Manolagas, SC ;
Jilka, RL .
ENDOCRINOLOGY, 2005, 146 (03) :1226-1235
[8]   Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways [J].
Alikhani, Mani ;
Alikhani, Zoubin ;
Boyd, Coy ;
MacLellan, Christine M. ;
Raptis, Markos ;
Liu, Rongkun ;
Pischon, Nicole ;
Trackman, Philip C. ;
Gerstenfeld, Louis ;
Graves, Dana T. .
BONE, 2007, 40 (02) :345-353
[9]  
BARRETTCONNOR E, 1992, JAMA-J AM MED ASSOC, V268, P3333
[10]  
Bertelloni S, 1992, Magnes Res, V5, P45